Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Double-Blind Trial of Inebilizumab in IgG4-Related Disease
jRCT2071210001Phase 3Active, not recruiting
- Sponsor
- Amgen
- Start
- Aug 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, double-blind trial in IgG4-related disease (IgG4-RD) comparing Inebilizumab arm with Placebo arm (2 arms). Primary endpoint: Time to disease flare. Started Aug 2021; status: active, not recruiting.
02
Drugs
inebilizumab
03
Conditions
IgG4-related disease (IgG4-RD)
Beyond the preview
Go deeper on jRCT2071210001.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071210001.